A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration approval for a form of breast cancer, the first U.S. approval for a drug for which the companies have high expectations.
The FDA announced Friday that it had approved the drug, which will be marketed as Datroway, for certain patients with advanced breast cancer. Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form of breast cancer last month, its first regulatory green light.
The list price of Datroway in the United States is approximately $4,900 per 100-milligram vial, and the recommended dose of the drug is 6 milligrams per kilogram of the patient’s weight every three weeks.
This article is reserved for STAT+ subscribers
Unlock this article – plus daily coverage and analysis of the pharmaceutical industry – by subscribing to STAT+.
Already have an account? Log in
See all packages
